Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907527 · ClinicalTrials.gov registry record · Phase 1
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma, sponsored by Precigen.
- Active
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
- 2
- Study locations
NCT03907527: Active Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma, sponsored by Precigen.
NCT03907527 is a Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma that is active but no longer recruiting, run by Precigen. The registered enrollment target is 71 participants, below the 122-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (42% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03907527, a Phase 1 study of Recurrent Ovarian Carcinoma and Recurrent Fallopian Tube Carcinoma, is active but no longer recruiting, sponsored by Precigen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body, that has come back and is resistant to platinum chemotherapy. Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them.
Primary Outcome
Toxicity grading will be evaluated according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 5.0 and monitoring of adverse events
Conditions Studied
Interventions
- BIOLOGICAL PRGN-3005 UltraCAR-T cells
Study Locations (2)
Maryland
- National Institutes of Health (NIH) - Bethesda
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2028-11-15 |
| Phase | Phase 1 |
What the registry record for NCT03907527 still lists
NCT03907527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 122-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (42% lower).
The record links to 10 conditions, with Recurrent Ovarian Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which PRGN-3005 UltraCAR-T cells is the first listed.
NCT03907527 reports a single indexed study location in Maryland, Washington.
Frequently Asked Questions
What is clinical trial NCT03907527 about?
NCT03907527 is a clinical study titled "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer". This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary perit...
What is the current status of trial NCT03907527?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2019-04-30. Estimated completion is 2028-11-15.
What conditions does trial NCT03907527 study?
This clinical trial studies the following conditions: Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma.
What interventions are being tested in trial NCT03907527?
The interventions under investigation include: PRGN-3005 UltraCAR-T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03907527?
This trial is sponsored by Precigen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03907527 being conducted?
This trial has 2 study locations across Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03907527's enrollment target sits among peer trials
71 13th of 39 higher than 27 of 39 other Recurrent Ovarian Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Ovarian Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
RECRUITING · Phase 1
-
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
RECRUITING · Phase 1
-
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
RECRUITING · Phase 1
-
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
RECRUITING · Phase 1
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI